Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-x
As presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAGE-A8 peptide presented by HLA-A*02:01—encouraging safety and a preliminary efficacy signal were observed in patients with head and neck cancers and melanoma, including those treated with both the engager and anti-PD-1.
